Cargando…

Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for Streptococcus suis Infection

Tulathromycin is the first member of the triamilide antimicrobial drugs that has been registered in more than 30 countries. The goal of this study is to provide a potential new indication of tulathromycin for Streptococcus suis infections. We investigated the pharmacokinetic and ex vivo pharmacodyna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yu-Feng, Peng, Hui-Min, Bu, Ming-Xiao, Liu, Ya-Hong, Sun, Jian, Liao, Xiao-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627010/ https://www.ncbi.nlm.nih.gov/pubmed/29033841 http://dx.doi.org/10.3389/fphar.2017.00684

Ejemplares similares

Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against Streptococcus suis in Piglets
por: Wang, Rui-Ling, et al.
Publicado: (2022)

PK-PD Analysis of Marbofloxacin against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2018)

Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model
por: Zhao, Yongda, et al.
Publicado: (2018)

PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against Streptococcus suis in Piglets
por: Huang, Anxiong, et al.
Publicado: (2022)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Combination Therapy Strategies Against Multiple-Resistant Streptococcus Suis
por: Yu, Yang, et al.
Publicado: (2018)

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Profiles of Tulathromycin in an Experimental Intraperitoneal Haemophilus parasuis Infection Model in Neutropenic Guinea Pigs
por: Guo, Li-li, et al.
Publicado: (2021)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model
por: Zhou, Qiaoyi, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against Streptococcus suis in Pigs
por: Somogyi, Zoltán, et al.
Publicado: (2022)

Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine Streptococcus suis infection
por: Luo, Wanhe, et al.
Publicado: (2021)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Sub-Minimum Inhibitory Concentrations of Rhubarb Water Extracts Inhibit Streptococcus suis Biofilm Formation
por: Ding, Wen-Ya, et al.
Publicado: (2017)

Inhibition of Streptococcus suis Adhesion and Biofilm Formation in Vitro by Water Extracts of Rhizoma Coptidis
por: Li, Yan-Hua, et al.
Publicado: (2018)

Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs
por: Huang, Lingli, et al.
Publicado: (2018)

The Influence of Shuttle-Shape Emodin Nanoparticles on the Streptococcus suis Biofilm
por: Ding, Wenya, et al.
Publicado: (2018)

Emergence and Mechanism of Resistance of Tulathromycin Against Mycoplasma hyopneumoniae in a PK/PD Model and the Fitness Costs of 23S rRNA Mutants
por: Xia, Xirui, et al.
Publicado: (2022)

Rutin Inhibits Streptococcus suis Biofilm Formation by Affecting CPS Biosynthesis
por: Wang, Shuai, et al.
Publicado: (2017)

PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing
por: Chen, Yewei, et al.
Publicado: (2020)

Gallic Acid Potentiates the Antimicrobial Activity of Tulathromycin Against Two Key Bovine Respiratory Disease (BRD) Causing-Pathogens
por: Rajamanickam, Karthic, et al.
Publicado: (2019)

Preparation of Aditoprim Injection against Streptococcus suis in Pigs and a Dose Regimen Based on Pharmacokinetic-Pharmacodynamic Modeling
por: Qu, Wei, et al.
Publicado: (2022)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward
por: Landersdorfer, Cornelia B., et al.
Publicado: (2021)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Dose Optimization of Aditoprim-Sulfamethoxazole Combinations Against Trueperella pyogenes From Patients With Clinical Endometritis by Using Semi-mechanistic PK/PD Model
por: Maan, Muhammad Kashif, et al.
Publicado: (2021)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis
por: Blondeau, Joseph M., et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against Actinobacillus pleuropneumoniae in a Porcine Tissue Cage Infection Model
por: Yao, Lihua, et al.
Publicado: (2022)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
por: Zyryanov, Sergey, et al.
Publicado: (2023)

Spectrum-Effect Relationships Between the Bioactive Ingredient of Syringa oblata Lindl. Leaves and Its Role in Inhibiting the Biofilm Formation of Streptococcus suis
por: Liu, Yan-Yan, et al.
Publicado: (2018)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus
por: Rox, Katharina, et al.
Publicado: (2022)

Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study
por: Huang, Anxiong, et al.
Publicado: (2022)

Future insights of pharmacological prevention for AKI post cardiopulmonary bypass surgery (based on PK/PD approach)
por: Permeisari, Dias
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jniltib9oa81tb0bhacl3g7k1v